Navigation Links
MUHC researchers identify biomarkers that could leadto early diagnosis of colorectal cancer
Date:10/30/2013

This news release is available in French.

MONTREAL, October 30, 2013 Diagnosing colorectal cancer (CRC) is complex; it relies on significant invasive tests and subjective evaluations. This process may soon become much easier thanks to a medical breakthrough by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC). The researchers have identified genetic changes in the colon lining, or mucosa, in colorectal cancer patients that could be used as biomarkers of the disease. That will allow doctors to diagnose patients earlier, more accurately and less invasively. The study, recently published online, in Cancer Prevention Research, has implications for the nearly one million people diagnosed annually worldwide.

"The gold standard of diagnosis is currently colonoscopy," says corresponding author of the study, Dr. Rima Rozen, a geneticist from the Departments of Human Genetics and Pediatrics at The Montreal Children's Hospital of the MUHC and McGill University. "This is an invasive procedure, where the physician looks for abnormal tissue or growths also known as polyps." Additionally, given surging demand for colonoscopies, this research may ultimately offer an alternative option for early diagnosis, paving the way for the reduction in wait time.

According to Dr. Rozen, who is also a researcher of the Medical Genetics and Genomics Axis at the RI-MUHC, having genetic biomarkers of CRC will enhance the diagnostic procedure. "This new method could help to avoid false negative findings, which can occur in 10 to 15 per cent of endoscopic procedures," she says. "The key is using the right genes. I believe the ones we have identified are good candidates."

Dr. Rozen and her colleagues first identified five possible abnormal marker genes in a colon cancer mouse model. They then confirmed that these candidate biomarker genes were also abnormal in tissue obtained from colon cancer patients. "Not only did this show that our mouse model mimics the human disease," says Dr. Rozen. "But more importantly, it identified genes that could be used for colorectal cancer diagnosis."

Interestingly, the abnormal patterns of these genes were detected in otherwise normal colon cells that were not near the tumor site. "CRC develops in different stages," says Dr. Rozen. "This finding suggests that it may be possible to take tissue samples in more accessible regions of the gastrointestinal tract or, ideally, in blood or stool, and look for biomarkers as an early indicator of disease."


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-934-1934 x71381
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Unpublished trial data violates an ethical obligation to study participants, say researchers
2. Einstein researchers lead panels at NIH Aging and Chronic Disease Symposium on Geroscience
3. GW researchers examine increased ER reimbursements after ACA insurance coverage expansions
4. U of M researchers identify key proteins influencing major immune strategies
5. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
6. Carnegie Mellon and University at Buffalo researchers improving transit for people with disabilities
7. Researchers discover a new protein fold with a transport tunnel
8. Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
9. Study by researchers at Saarland University demonstrates preventive effect of sterols in Alzheimers
10. Neurotoxin effectively relieves bone cancer pain in dogs, Penn researchers find
11. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... announced today the addition of an affiliate in Minneapolis-St. Paul, MN, Dr. Adam ... accelerated detox, Naltrexone therapy and aftercare planning through his Timewise Medical practice in ...
(Date:9/25/2017)... ... 2017 , ... SyncDog, Inc., the leading ISV ... will be available in a managed cloud services model, available from its new ... new enhancements including support for caller ID and network sharing for remote users, ...
(Date:9/25/2017)... Church, VA (PRWEB) , ... September 25, 2017 ... ... & Trump, **An FDAnews Webinar**, Oct. 12, 2017 — 1:30 p.m. – 3:00 ... off to a running start. Just look what’s happened in four short months:, ...
(Date:9/25/2017)... ... September 25, 2017 , ... The award is named in honor of Betty ... year the award is given to those who exemplify the mission of Community Options ... in communities of their choosing. Recent recipients of this award include Governor Tom Kean, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough ... or 1980s, with headgear so wired up and containing so much metal that jokes ... so discreet that its treatments can barely be observed. As a result, it’s now ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology: